118 related articles for article (PubMed ID: 38097920)
21. Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma.
Kim HS; DO SI; Kim DH; Apple S
Anticancer Res; 2020 Mar; 40(3):1487-1494. PubMed ID: 32132048
[TBL] [Abstract][Full Text] [Related]
22. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
23. Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.
Van Bockstal MR; Cooks M; Nederlof I; Brinkhuis M; Dutman A; Koopmans M; Kooreman L; van der Vegt B; Verhoog L; Vreuls C; Westenend P; Kok M; van Diest PJ; Nauwelaers I; Laudus N; Denkert C; Rimm D; Siziopikou KP; Ely S; Zardavas D; Roberts M; Floris G; Hartman J; Acs B; Peeters D; Bartlett JMS; Dequeker E; Salgado R; Giudici F; Michiels S; Horlings H; van Deurzen CHM
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638394
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
25. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
[TBL] [Abstract][Full Text] [Related]
27. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):258-264. PubMed ID: 33030848
[TBL] [Abstract][Full Text] [Related]
28. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
[TBL] [Abstract][Full Text] [Related]
29. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Azim HA; Shohdy KS; Elghazawy H; Salib MM; Almeldin D; Kassem L
Biomarkers; 2022 Dec; 27(8):764-772. PubMed ID: 35980714
[TBL] [Abstract][Full Text] [Related]
30. Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.
Imanishi S; Morishima H; Gotoh T
Jpn J Clin Oncol; 2022 Oct; 52(10):1167-1175. PubMed ID: 35766179
[TBL] [Abstract][Full Text] [Related]
31. Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
Tomioka N; Hatanaka KC; Okuyama D; Watanabe KI; Yamamoto M; Maeda H; Tachikawa H; Kuwahara S; Shimizu A; Suzuki H; Hatanaka Y; Takahashi M
Breast Cancer; 2023 May; 30(3):497-505. PubMed ID: 36892732
[TBL] [Abstract][Full Text] [Related]
32. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Sun WY; Lee YK; Koo JS
J Transl Med; 2016 Jun; 14(1):173. PubMed ID: 27286842
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.
Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
[TBL] [Abstract][Full Text] [Related]
36. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
37. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
[TBL] [Abstract][Full Text] [Related]
38. Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer.
Woo JW; Han EK; Suh KJ; Kim SH; Kim JH; Park SY
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38753066
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
Grabenstetter A; Jungbluth AA; Frosina D; Hoda R; Dos Anjos CH; Patil S; Sevilimedu V; Weigelt B; Reis-Filho JS; Zhang H; Traina T; Robson ME; Brogi E; Wen HY
Am J Surg Pathol; 2021 Sep; 45(9):1274-1281. PubMed ID: 34115674
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.
Sahin Ozkan H; Ugurlu MU; Yumuk PF; Kaya H
Pathol Oncol Res; 2020 Oct; 26(4):2733-2745. PubMed ID: 32681436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
